{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:48:46Z","timestamp":1794350926981,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.berh.2023.101859","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:54:46Z","timestamp":1692705286000},"page":"101859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Musculoskeletal manifestations of systemic lupus erythematosus"],"prefix":"10.1016","volume":"37","author":[{"given":"Anastasiia","family":"Shumilova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib1","first-page":"527","article-title":"Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for Rheumatology research. I. A descriptive analysis of 704 European lupus patients. European consensus study group for disease activity in SLE","volume":"10","author":"Vitali","year":"1992","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/03009742.2012.677857","article-title":"An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life","volume":"41","author":"Pettersson","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"14","key":"10.1016\/j.berh.2023.101859_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203309345784","article-title":"Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors","volume":"18","author":"Baker","year":"2009","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.berh.2023.101859_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acr.20669","article-title":"Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus","volume":"64","author":"Yelin","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2023.101859_bib5","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.38731","article-title":"Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis","volume":"66","author":"Thomas","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101859_bib6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/kew049","article-title":"Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry","volume":"55","author":"Pego-Reigosa","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.03.022","article-title":"Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment","volume":"47","author":"Ceccarelli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"13","key":"10.1016\/j.berh.2023.101859_bib8","first-page":"246","article-title":"[Chronic acute postrheumatic arthropathy: its relation to secondary polyarthritis and Jaccoud's syndrome]","volume":"151","author":"Bywaters","year":"1967","journal-title":"Bull Acad Natl Med"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181632d18","article-title":"Jaccoud arthropathy in systemic lupus erythematosus","volume":"87","author":"Santiago","year":"2008","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.berh.2023.101859_bib10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/09612033221082908","article-title":"Jaccoud-type lupus arthropathy","volume":"31","author":"Santiago","year":"2022","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.berh.2023.101859_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.51.3.358","article-title":"Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response?","volume":"51","author":"Spronk","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000405","article-title":"Jaccoud-type lupus arthropathy: practical classification criteria","volume":"7","author":"Santiago","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib13","first-page":"65","article-title":"Deforming arthropathy of the hands in systemic lupus erythematosus","volume":"15","author":"Alarc\u00f3n-Segovia","year":"1988","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3899\/jrheum.081067","article-title":"Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion?","volume":"36","author":"Amezcua-Guerra","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101859_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102612","article-title":"Rhupus: a systematic literature review","volume":"19","author":"Antonini","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib16","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2012.321","article-title":"Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?","volume":"64","author":"Taraborelli","year":"2012","journal-title":"Reumatismo"},{"issue":"13","key":"10.1016\/j.berh.2023.101859_bib17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1177\/09612033211051637","article-title":"Erosive arthritis in systemic lupus erythematosus: not only Rhupus","volume":"30","author":"Ceccarelli","year":"2021","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.berh.2023.101859_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/0961203314540967","article-title":"Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"23","author":"Budhram","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-018-1622-z","article-title":"Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus","volume":"20","author":"Ceccarelli","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101859_bib20","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/b8gaty","article-title":"Erosive arthritis in systemic lupus erythematosus: application of cluster analysis","author":"Ceccarelli","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Toukap","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2023.101859_bib22","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1136\/ard.2005.040477","article-title":"Expression of interferon \u03b2 in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis","volume":"64","author":"Van Holten","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101859_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/ar1165","article-title":"Treatment with recombinant interferon-\u03b2 reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis","volume":"6","author":"Van Holten","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2023.101859_bib24","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1002\/art.21496","article-title":"Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-\u03b2-deficient mice","volume":"52","author":"Treschow","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2023.101859_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/art.27312","article-title":"Mediation of nonerosive arthritis in a mouse model of lupus by interferon-\u03b1-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis","volume":"62","author":"Mensah","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74391-4","article-title":"Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis","volume":"10","author":"Hubbard","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cei.13585","article-title":"Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid","volume":"205","author":"Sippl","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.berh.2023.101859_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40744-022-00442-z","article-title":"A\u00a0narrative literature review comparing the key features of musculoskeletal involvement in rheumatoid arthritis and systemic lupus erythematosus","volume":"9","author":"D\u00f6rner","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/0961203319834671","article-title":"Ultrasound in the assessment of musculoskeletal involvement in systemic lupus erythematosus: state of the art and perspectives","volume":"28","author":"Di Matteo","year":"2019","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.berh.2023.101859_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11926-021-01040-8","article-title":"Imaging of joint and soft tissue involvement in systemic lupus erythematosus","volume":"23","author":"Di Matteo","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2023.101859_bib31","doi-asserted-by":"crossref","first-page":"kev343","DOI":"10.1093\/rheumatology\/kev343","article-title":"The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review","author":"Zayat","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2023.101859_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/key277","article-title":"Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus","volume":"58","author":"Zayat","year":"2019","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2023.101859_bib33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1177\/0961203320947149","article-title":"Prevalence of subclinical synovitis of the hand in patients with systemic lupus erythematosus","volume":"29","author":"Guill\u00e9n-Astete","year":"2020","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.10753","article-title":"Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging","volume":"48","author":"Ostendorf","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2023.101859_bib35","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1093\/rheumatology\/keab288","article-title":"Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation for mUsculoskeletal Lupus longitudinal multicentre study","volume":"60","author":"Mahmoud","year":"2021","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2023.101859_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/rheumatology\/key422","article-title":"Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus","volume":"58","author":"Mahmoud","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13075-016-1125-8","article-title":"Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography","volume":"18","author":"Piga","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2023.101859_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00256-014-2033-0","article-title":"MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects","volume":"44","author":"Chiara","year":"2015","journal-title":"Skeletal Radiol"},{"issue":"10","key":"10.1016\/j.berh.2023.101859_bib39","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/rheumatology\/keu215","article-title":"A\u00a0study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status","volume":"53","author":"Ball","year":"2014","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2023.101859_bib40","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101859_bib41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2023.101859_bib42","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/keab883","article-title":"Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index","volume":"61","author":"Carter","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101859_bib43","article-title":"Revision to the musculoskeletal domain of the BILAG-2004 index to incorporate ultrasound findings","author":"Sandler","year":"2023","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The systemic lupus erythematosus responder index (SRI); A new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2023.101859_bib46","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/annrheumdis-2022-eular.5149","article-title":"AB0571 derivation and independent validation of the lupus arthritis and musculoskeletal disease activity score (LAMDA): a more sensitive, specific and responsive tool for lupus arthritis","volume":"81","author":"Mahmoud","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101859_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2023.101859_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215411","article-title":"Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort","volume":"79","author":"Hassan","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2023.101859_bib49","first-page":"1275","article-title":"Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro","year":"1999","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2023.101859_bib50","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2023.101859_bib51","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight\u2013week randomized, double-blind trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2023.101859_bib52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","article-title":"Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis","volume":"30","author":"Schiff","year":"2010","journal-title":"Clin Drug Invest"},{"issue":"9","key":"10.1016\/j.berh.2023.101859_bib53","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib54","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2023.101859_bib55","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.berh.2023.101859_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2023.101859_bib57","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101859_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2023.101859_bib59","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101859_bib60","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101859_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000907","article-title":"Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks","volume":"10","author":"Neupane","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1016\/j.berh.2023.101859_bib62","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2217\/cer-2022-0040","article-title":"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus","volume":"11","author":"Bruce","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.berh.2023.101859_bib63","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled","volume":"392","author":"Wallace","year":"2018"},{"issue":"10381","key":"10.1016\/j.berh.2023.101859_bib64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.berh.2023.101859_bib65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101859_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221086719","article-title":"A\u00a0glimpse into the future of systemic lupus erythematosus","volume":"14","author":"Aringer","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T01:36:33Z","timestamp":1729215393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521694223000451"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101859","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Musculoskeletal manifestations of systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101859"}}